On June 25, Ascendis Pharma rose 8.3% in regular trading, trading at approximately $259.16/share, with turnover of $327 million. The rally was driven by the market continuing to digest strong long-term clinical data for the company's core product Yorvipath in treating hypoparathyroidism, alongside favorable analyst coverage.

Specifically, the Phase 3 PaTHway study's 3.5-year data demonstrated a composite response rate of 86%, with 89% of patients completing the trial. The Phase 2 PaTH Forward study's 5-year data showed an 82% response rate, with sustained improvement in kidney function — mean estimated glomerular filtration rate increased by 9.4 mL/min/1.73 square meters from baseline. Wedbush issued a research note stating that Yorvipath maintains a superior clinical profile relative to competitors, reiterating an outperform rating and $273 price target.

Notably, competitor MBX Biosciences reported only a 57% composite response rate in its Phase 2 trial for the same indication, further underscoring Yorvipath's leading position in the hypoparathyroidism treatment landscape.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)